Biogen's anti-tau Alzheimer's drug misses Phase 2 goal, but claims signs of efficacy

Biogen's latest Alzheimer's drug, BIIB080, has failed to meet its primary endpoint in a Phase 2 clinical trial. Despite this setback, the company claims to have observed signs of efficacy, raising questions about the drug's potential in treating the disease.